biostudies-literatureUnknown63(5)Poola S<h4>Background</h4>Hepatitis B virus (HBV) reactivation is a serious complication in patients receiving chronic immunosuppression. Anti-CD20 agents such as Rituximab are considered high risk for HBV reactivation (> 10%); therefore, antiviral prophylaxis is recommended for all anti-HBc positive patients. Some studies have suggested that patients with resolved HBV infection and higher hepatitis B surface antibody (anti-HBs) titer have a higher level of protection against reactivation.<h4>Aim</h4>The purpose of this study was to systematically review the role of anti-HBs titer on HBV reactivation in patients on rituximab while not on antiviral therapy/prophylaxis.<h4>Methods</h4>We systematically reviewed all studies that discussed HBV reactivation in patients on rituximab therapy with resolvAlimentary pharmacology & therapeutics592-602https://www.ebi.ac.uk/biostudies/studies/S-EPMC12904191biostudies-literatureMeta-Analysis: High anti-HBs Titers are Associated with Significantly Reduced Risk of Hepatitis B Virus Reactivation During Rituximab Treatment.PMC12904191Sewell KYang ZPoola SKratzer MTillmann HLfalseMeta-Analysis: High anti-HBs Titers are Associated with Significantly Reduced Risk of Hepatitis B Virus Reactivation During Rituximab Treatment.<h4>Background</h4>Hepatitis B virus (HBV) reactivation is a serious complication in patients receiving chronic immunosuppression. Anti-CD20 agents such as Rituximab are considered high risk for HBV reactivation (> 10%); therefore, antiviral prophylaxis is recommended for all anti-HBc positive patients. Some studies have suggested that patients with resolved HBV infection and higher hepatitis B surface antibody (anti-HBs) titer have a higher level of protection against reactivation.<h4>Aim</h4>The purpose of this study was to systematically review the role of anti-HBs titer on HBV reactivation in patients on rituximab while not on antiviral therapy/prophylaxis.<h4>Methods</h4>We systematically reviewed all studies that discussed HBV reactivation in patients on rituximab therapy with resolv2026-01-01T00:00:00Z2026 Mar2026-07-15T16:39:11.273Z2026-07-07T03:08:26.98ZS-EPMC129041914139094610.1111/apt.70490